Ironwood Beats Q3 Estimates, Lifts 2026 Revenue and EBITDA Outlook
IRWD has more than doubled off its 52-week low of $1.76.
Summary
Q3 revenue came in at $133.04M against a $121.57M consensus, and adjusted EBITDA hit $97.93M versus $85.73M expected. Adjusted net income of $60.05M also cleared the $51.95M estimate. Management raised full-year 2026 guidance for the second straight quarter: LINZESS U.S. net sales to $1.20-$1.25B, total revenue to $485-$510M, and adjusted EBITDA above $350M. The beat was driven by 4.9% LINZESS prescription demand growth, partly offset by a low single-digit net price decline, plus lower total costs and expenses. This follows the October 16 announcement that Tammi Gaskins becomes CEO on January 1, 2027, with Tom McCourt retiring.
At the time of this announcement, IRWD was trading at $4.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $623M. The 52-week trading range was $1.76 to $5.78. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.